ReviewScience translational medicine2012
Raising the bar: the curative potential of human cancer immunotherapy.
Review in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02280811 (A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers), which is not on this map. Cited by 141 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers
Who cites it
141 citing papers in PubMed, 242 citations in OpenAlex.
- Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.Cell biomaterials · 2026Article
- Natural and Engineered Cytokines as Cancer Therapeutics.Annual review of cancer biology · 2026Article
- Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.Molecular therapy. Nucleic acids · 2025Article
- A New Protein-Ligand Trapping System to Rapidly Screen and Discover Small-Molecule Inhibitors of PD-L1 from Natural Products.Molecules (Basel, Switzerland) · 2025Article
- Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study.JCO oncology practice · 2025Article
- HScience advances · 2024Article
- Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.Journal of hematology & oncology · 2024Review
- Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review.Medical oncology (Northwood, London, England) · 2024Review
- Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.Theranostics · 2024Article
- Treg-targeted IL-2/anti-IL-2 complex controls graft-Haematologica · 2024Article
- The decreased of peripheral blood natural killer cell is associated with serum IL-2 level in the renal tubular acidosis in patients with primary sjogren's syndrome.BMC immunology · 2023Article
- Review
- Review
- Review
- Editorial: Biomarkers in the era of cancer immunotherapy: zooming in from the periphery to the tumor microenvironment.Frontiers in immunology · 2023Article
- Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Article
- Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development.Oncology letters · 2022Review
- Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants.HLA · 2022Article
- A Darwinian perspective on tumor immune evasion.Biochimica et biophysica acta. Reviews on cancer · 2022Review
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.